{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:49:00Z","timestamp":1794948540336,"version":"4.9.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T00:00:00Z","timestamp":1693353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K23 AR075872"],"award-info":[{"award-number":["K23 AR075872"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24 AR080217"],"award-info":[{"award-number":["K24 AR080217"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30 AR070254"],"award-info":[{"award-number":["P30 AR070254"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01 AR073208"],"award-info":[{"award-number":["R01 AR073208"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rheumatology Research Foundation K Supplement"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The objective of this study was to determine baseline risk factors for requiring immunosuppression and having persistent arthritis in patients with immune checkpoint inhibitor\u2013induced inflammatory arthritis (ICI\u2013inflammatory arthritis).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants were adults with rheumatologist diagnosed ICI\u2013inflammatory arthritis. The primary outcome was requirement of conventional synthetic (cs) or biologic (b) DMARDs; other outcomes were persistence of inflammatory arthritis &amp;gt;6\u2009months after ICI cessation and requirement of CSs. Logistic regression models evaluated associations between clinical features and primary and secondary outcomes, with adjustment for potential confounders, as appropriate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>One hundred and twenty-six patients with ICI\u2013inflammatory arthritis were included; 53 patients (42%) required a csDMARD\/bDMARD. In the univariate logistic regression analysis, higher clinical disease activity index (CDAI), tenosynovitis, longer symptom duration before first rheumatology visit and longer ICI duration were significantly associated with a higher likelihood of requiring DMARDs; in addition, there was a trend towards those treated with prior chemotherapy being less likely to need DMARDs. After adjustment, tenosynovitis, longer symptom duration and higher CDAI remained associated with requiring DMARDs, while those with prior chemotherapy were significantly less likely to require DMARDs. Combination anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein-4)\/PD-1 (Programmed cell death protein-1) therapy and CS use at baseline were associated with a higher risk of persistent inflammatory arthritis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Higher levels of disease activity, tenosynovitis and longer symptom duration prior to rheumatology referral were associated with requiring DMARDs for ICI\u2013inflammatory arthritis, while those treated previously with chemotherapy were less likely to require additional immunosuppression. The presence of risk factors for severe disease at baseline may indicate a role for higher initial CS dose, earlier rheumatology referral, and adoption of immunosuppression beyond CSs to improve outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/kead438","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T21:47:20Z","timestamp":1693432040000},"page":"1518-1522","source":"Crossref","is-referenced-by-count":12,"title":["Baseline predictors of disease severity in immune checkpoint inhibitor-induced inflammatory arthritis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-7059","authenticated-orcid":false,"given":"Laura C","family":"Cappelli","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Medicine, St. Agnes Hospital , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4752-5029","authenticated-orcid":false,"suffix":"III","given":"Clifton O","family":"Bingham","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami A","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins School of Medicine , Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,30]]},"reference":[{"key":"2024060322013791600_kead438-B1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"2024060322013791600_kead438-B2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2024060322013791600_kead438-B3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024060322013791600_kead438-B4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41584-018-0074-9","article-title":"Rheumatic immune-related adverse events from cancer immunotherapy","volume":"14","author":"Calabrese","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024060322013791600_kead438-B5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s41927-020-00133-8","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis: a qualitative study identifying unmet patient needs and care gaps","volume":"4","author":"Cappelli","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2024060322013791600_kead438-B6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/acr2.1026","article-title":"Sonographic findings in inflammatory arthritis secondary to immune checkpoint inhibition: a case series","volume":"1","author":"Albayda","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2024060322013791600_kead438-B7","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RHU.0000000000001370","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2024060322013791600_kead438-B8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2024060322013791600_kead438-B9","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41467-022-29539-3","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"2024060322013791600_kead438-B10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.41949","article-title":"Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer","volume":"74","author":"Cunningham-Bussel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2024060322013791600_kead438-B11","doi-asserted-by":"crossref","first-page":"e003779","DOI":"10.1136\/jitc-2021-003779","article-title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","volume":"10","author":"Jing","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2024060322013791600_kead438-B12","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2024060322013791600_kead438-B13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejca.2021.08.048","article-title":"The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: a prospective study of the French REISAMIC registry","volume":"158","author":"Ruste","year":"2021","journal-title":"Eur J Cancer"},{"key":"2024060322013791600_kead438-B14","doi-asserted-by":"crossref","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/kead438\/51441821\/kead438.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/6\/1518\/58064763\/kead438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/6\/1518\/58064763\/kead438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T23:43:32Z","timestamp":1717458212000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/6\/1518\/7255905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,30]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,8,30]]},"published-print":{"date-parts":[[2024,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kead438","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2023,8,30]]}}}